Wright Medical Group N.V. Highlights New Innovations at the American Orthopaedic Foot and Ankle Society (AOFAS) 2017 Annual M...
July 12 2017 - 6:00AM
Wright Medical Group N.V. (NASDAQ:WMGI) today announced that it
will highlight new innovations at the American Orthopaedic Foot and
Ankle Society (AOFAS) 2017 Annual Meeting taking place at the
Washington State Convention Center in Seattle, Washington from July
12-15, 2017.
Wright will feature its full range of lower extremities and
biologics products at exhibit booth #801 and will showcase, for the
first time, three important additions to its foot and ankle
portfolio:
INVISION™ Total Ankle Revision System – The
first and only system developed specifically for total ankle
revision arthroplasty, the INVISION Total Ankle Revision System
provides a unique solution for even the most difficult revision
procedures. Whether leveraged as a standalone construct or in
conjunction with INFINITY and INBONETM components, the INVISION
Total Ankle Revision System is an important addition to the
continuum of care from total ankle replacement through any
necessary revisions. The INVISION Total Ankle Revision System
helps surgeons re-build bone lost through previous surgeries and
provides modularity to help restore natural joint height.
ORTHOLOC™ 3Di Ankle Fracture Low Profile System
– The ORTHOLOC 3Di Ankle Fracture Low Profile System features a
complete range of ankle fracture plates designed specifically for
the foot and ankle surgeon. The system features low-profile,
anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw
technology, providing an innovative fracture solution that
addresses a primary need for one of the foot and ankle’s largest
market segments.
MICA™ Minimally-Invasive Foot & Ankle
System – As the first minimally invasive solution
specifically designed for foot and ankle surgery, the MICA
Minimally-Invasive Foot & Ankle System provides a minimally
disruptive, procedurally integrated solution that features
specifically designed implants and instrumentation for percutaneous
surgery of the foot. The MICA Minimally-Invasive Foot &
Ankle System can be used to treat multiple pathologies including
one of the most common, Hallux Valgus, commonly known as bunions.
Compared to a traditional open surgery, the MICA
Minimally-Invasive Foot & Ankle System has been shown to
provide less pain, shorter operative times and improved
cosmesis.
Robert Palmisano, president and chief executive officer,
commented, “We have continued to expand our best-in-class foot and
ankle product portfolio to meet the needs of orthopaedic physicians
and patients and further extend our leadership position in the fast
growing lower extremities and biologics markets. The launch
of our unique INVISION Total Ankle Revision System will expand our
leadership in total ankle technology and highlights our ability to
address the total ankle replacement continuum of care. In
addition, the ORTHOLOC 3Di Ankle Fracture Low Profile System and
MICA Minimally-Invasive Foot & Ankle System further enhances
our offering in the foot and ankle market space and allows for an
improved surgical experience.”
Wright is also conducting medical education and training courses
during the AOFAS annual meeting in its mobile training lab.
These courses will address total ankle arthroplasty, Charcot
reconstruction and limb salvage, and ankle and hindfoot fusion
using Augment®. More information on Wright Medical’s products
can be found at www.wright.com.
Internet Posting of Information
Wright routinely posts information that may be important to
investors in the “Investor Relations” section of its website at
www.wright.com. The company encourages investors and
potential investors to consult the Wright website regularly for
important information about Wright.
About Wright Medical Group N.V.
Wright Medical Group N.V. is a global medical device company
focused on extremities and biologics products. The company is
committed to delivering innovative, value-added solutions improving
the quality of life for patients worldwide. Wright is a
recognized leader of surgical solutions for the upper extremities
(shoulder, elbow, wrist and hand), lower extremities (foot and
ankle) and biologics markets, three of the fastest growing segments
in orthopaedics. For more information about Wright, visit
www.wright.com.
™ and ® denote trademarks and registered trademarks of Wright
Medical Group N.V. or its affiliates, registered as indicated
in the United States, and in other countries. All other
trademarks and trade names referred to in this release are the
property of their respective owners.
Cautionary Note Regarding Forward-Looking
Statements
This release includes forward-looking statements under the
Private Securities Litigation Reform Act of 1995.
These forward-looking statements generally can be identified
by the use of words such as “anticipate,” “expect,” “intend,”
“could,” “may,” “will,” “believe,” “estimate,” “look forward,”
“forecast,” “goal,” “target,” “project,” “continue,”
“outlook,” “guidance,” “future,” other words of similar meaning and
the use of future dates. Forward-looking statements in this
release include, but are not limited to, statements about the
performance and market acceptance of the company’s products.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Each forward-looking
statement contained in this release is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others, physician acceptance,
endorsement, and use of company products; the effect of regulatory
actions, changes in and adoption of reimbursement rates; product
liability claims; product recalls; the effects of industry,
economic or political conditions outside of the company’s control;
competitor activities; and the risks identified under the heading
“Risk Factors” in Wright’s Annual Report on Form 10-K for the year
ended December 25, 2016 filed by Wright with the SEC on February
23, 2017 and in other subsequent SEC filings by Wright. Investors
should not place considerable reliance on the forward-looking
statements contained in this release. Investors are encouraged to
read Wright’s filings with the SEC, available at www.sec.gov, for a
discussion of these and other risks and uncertainties. The
forward-looking statements in this release speak only as of the
date of this release, and Wright undertakes no obligation to update
or revise any of these statements. Wright’s business is subject to
substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.
Investors & Media:
Julie D. Tracy
Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V.
(901) 290-5817
julie.tracy@wright.com
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Apr 2023 to Apr 2024